Please select the option that best describes you:
How does your treatment approach vary in patients with HR+/HER2- breast cancer presenting with CNS metastases?
While rare, these patients were excluded from all frontline CDK4/6 inhibitor trials. Is there any data on the efficacy of ribociclib in the CNS or ability to cross BBB as there is for abemaciclib?
Answer from: Medical Oncologist at Academic Institution
There are preclinical studies published about ribociclib entering the CNS (Patel et al., PMID 31079218), as well as some clinical studies in non-breast tumors such as meningiomas (Sanai et al., ESMO 2019). However, I am not aware of any published studies in ribociclib analogous to the Phase 2 trial ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Besides abemaciclib, ribociclib can cross BBB as well and there is some data to support this, albeit limited to case reports and real-world setting: Radke et al., PMID 33224000Cottu et al., Annals of Oncology 2019